NEW YORK (GenomeWeb News) –Metabolon and Charles River Discovery Services are partnering to advance cancer research.
The deal, which was officially announced this week, leverages Metabolon's metabolomics technology with Charles River's preclinical oncology expertise.
Together, they will provide customers services focused on identifying, characterizing, and validating drug target candidates; pharmacokinetic and pharmacodynamic, tumor growth delay, tumor growth inhibition, survival, combination, and adjuvant study designs; and development of biomarkers for preclinical pharmacodynamic work, patient stratification and selection, and translational models and efficacy.
Financial and other terms of the deal were not disclosed.
Metabolon is a metabolomics-based diagnostics and services firm. Charles River Discovery Services, part of Charles River Laboratories, provides products for early compound in vitro screening and differentiation.